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Fluconazole in vitro susceptibility test results for 205,329 yeasts were collected from 134 study sites in 40
countries from June 1997 through December 2005. Data were collected for 147,776 yeast isolates tested with
voriconazole from 2001 through 2005. All investigators tested clinical yeast isolates by the CLSI M44-A disk
diffusion method. Test plates were automatically read and results recorded with a BIOMIC image analysis
system. Species, drug, zone diameter, susceptibility category, and quality control results were collected quar-
terly. Duplicate (same patient, same species, and same susceptible-resistant biotype profile during any 7-day
period) and uncontrolled test results were not analyzed. Overall, 90.1% of all Candida isolates tested were
susceptible (S) to fluconazole; however, 10 of the 22 species identified exhibited decreased susceptibility (<75%
S) on the order of that seen with the resistant (R) species C. glabrata and C. krusei. Among 137,487 isolates of
Candida spp. tested against voriconazole, 94.8% were S and 3.1% were R. Less than 30% of fluconazole-resistant
isolates of C. albicans, C. glabrata, C. tropicalis, and C. rugosa remained S to voriconazole. The non-Candida
yeasts (8,821 isolates) were generally less susceptible to fluconazole than Candida spp. but, aside from
Rhodotorula spp., remained susceptible to voriconazole. This survey demonstrates the broad spectrum of these
azoles against the most common opportunistic yeast pathogens but identifies several less common yeast species
with decreased susceptibility to antifungal agents. These organisms may pose a future threat to optimal
antifungal therapy and emphasize the importance of prompt and accurate species identification.
Although the list of opportunistic fungi causing serious, life-
threatening infection increases every year (1, 6, 17, 24, 30, 44),
without question the single most important cause of opportu-
nistic mycoses worldwide remains Candida species (34). De-
spite fewer infections, the opportunistic yeasts other than Can-
dida species, led by Cryptococcus neoformans, also cause
disastrous infections in the most fragile immunocompromised
patients (3, 24, 44).
More than 20 different species of Candida have been re-
ported as etiologic agents of invasive candidiasis in humans (8,
24). Although more than 90% of invasive infections due to
Candida spp. can be attributed to five species, C. albicans, C.
glabrata, C. parapsilosis, C. tropicalis, and C. krusei, the list of
reported species continues to grow as laboratories are pushed
to provide an identification to the species level as an aid in
optimizing therapy of candidal infections (20, 31, 32, 34, 41).
Likewise, the diverse array of opportunistic yeasts and yeast-
like fungi and their variable susceptibilities to both new and
established antifungal agents has made the need for prompt
identification of noncandidal yeasts from clinical material
much more compelling (24, 40, 44). Our understanding of the
frequency of occurrence and the antifungal susceptibility of
both Candida and non-Candida yeasts has been enhanced in
recent years through the efforts of several large surveillance
programs conducted throughout the world (2, 7, 9, 13, 19, 23,
26, 34, 37, 45).
Among the fungal surveillance programs, the ARTEMIS
Global Antifungal Surveillance Program is the largest and
most comprehensive in that it includes both Candida and non-
Candida yeasts, is both longitudinal (8 years in duration,
1997-present) and global (134 institutions in 40 countries) in
scope, employs standardized in vitro susceptibility testing
methods used for “routine” testing in participating laboratories
and for “reference” testing in a central reference laboratory,
uses electronic data capture and storage in a central database,
and conducts external validation of the data generated by the
participating laboratories (9, 13, 25–27, 31, 32). In 2005, we
reported the results from the ARTEMIS DISK Global Anti-
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fungal Surveillance Program in which species identification
and the fluconazole and voriconazole antifungal susceptibility
profiles were determined for 134,715 consecutive clinical iso-
lates of Candida and 6,052 isolates of noncandidal yeasts col-
lected from cases of mucosal and invasive fungal infections in
127 medical centers in 39 countries over a 6.5-year period
(1997 through 2003) (26). In the present study, we expand the
ARTEMIS database to include the time period from June
1997 through December 2005 and a total of 205,329 yeast
isolates (196,508 isolates of Candida and 8,821 isolates of non-
candidal yeasts) from 134 study sites in 40 countries. We pro-
vide comparative susceptibility data for fluconazole and vori-
conazole for 147,766 isolates collected from 2001 to 2005 and
include an analysis of resistance rates by year, geographic re-
gion, hospital location, and clinical specimen type for selected
species.
MATERIALS AND METHODS
Organisms and test sites. A total of 196,508 isolates of Candida spp. and 8,821
isolates of noncandidal yeasts obtained from 134 different medical centers in the
Asia-Pacific region (28 sites), Latin America (16 sites), Europe (66 sites), the
Africa/Middle East region (11 sites), and North America (13 sites) were collected
and tested against fluconazole between June 1997 and December 2005. In ad-
dition, a total of 147,766 isolates (141,229 isolates of Candida spp. and 6,379
other yeasts) from 124 study sites in 35 countries were tested against voricon-
azole between 2001 and 2005. Approximately 80% of the study sites participated
in the survey for 3 or more years (average duration of participation, 4.2 years;
range, 1 to 8 years).
All yeasts considered pathogens from all body sites (e.g., blood, normally
sterile body fluids, deep tissue, genital tract, gastrointestinal tract, respiratory
tract, and skin and soft tissue) and isolates from patients in all in-hospital
locations during the study period were tested. Yeasts considered by the local site
investigator to be colonizers, that is, not associated with an obvious pathology,
were excluded, as were duplicate isolates from a given patient (same species and
same susceptible-resistant biotype profile within any 7-day period). The identi-
fication of isolates was performed locally in accordance with each site’s routine
methods. The majority (76%) of the study sites employed one or more com-
mercially available yeast identification systems (API, Vitek, and/or MicroScan)
supplemented by classical biochemical and morphological methods, and the
remainder used the classical methods alone (8, 9).
Susceptibility test method. Disk diffusion testing of fluconazole and voricon-
azole was performed as described by Hazen et al. (9) and in CLSI (formerly
NCCLS) document M44-A (16). Agar plates (90-, 100-, or 150-mm diameter)
containing Mueller-Hinton agar (obtained locally at all sites) supplemented with
2% glucose and 0.5 g of methylene blue per ml at a depth of 4.0 mm were used.
The agar surface was inoculated by using a swab dipped in a cell suspension
adjusted to the turbidity of a 0.5 McFarland standard. Fluconazole (25 g) and
voriconazole (1 g) disks (Becton Dickinson, Sparks, MD) were placed onto the
surfaces of the inoculated plates, and the plates were incubated in air at 35 to
37°C and read at 18 to 24 h. Slowly growing isolates, primarily members of the
genus Cryptococcus, were read after 48 h of incubation. Zone diameter endpoints
were read at 80% growth inhibition by using a BIOMIC image analysis plate
reader system (Giles Scientific, Santa Barbara, CA) (9, 25–27).
The interpretive criteria for the fluconazole and voriconazole disk diffusion
tests were those of the CLSI (16, 28, 29): susceptible (S), zone diameters of 19
mm (fluconazole) and 17 mm (voriconazole); susceptible dose dependent
(SDD), zone diameters of 15 to 18 mm (fluconazole) and 14 to 16 mm (vori-
conazole); and resistant (R), zone diameters of 14 mm (fluconazole) and 13
mm (voriconazole). The corresponding MIC breakpoints (16, 28, 29) are as
follows: S, MICs of 8 g/ml (fluconazole) and 1 g/ml (voriconazole); SDD,
MICs of 16 to 32 g/ml and 2 g/ml (voriconazole); and R, MICs of 64 g/ml
(fluconazole) and 4 g/ml (voriconazole).
QC. Quality control (QC) was performed in accordance with CLSI document
M44-A (16) by using Candida albicans ATCC 90029 and C. parapsilosis ATCC
22019. A total of 14,484 and 10,146 QC results were obtained for fluconazole and
voriconazole, respectively, of which more than 99% were within the acceptable
limits.
Analysis of results. All yeast disk test results were read by electronic image
analysis and interpreted and recorded with the BIOMIC plate reader system
(Giles Scientific, Inc.). Test results were sent by e-mail to Giles Scientific for
analysis. The zone diameter, susceptibility category (S, SDD, or R), and QC test
results were all recorded electronically. Patient and doctor names, duplicate
test results (same patient, same species, and same biotype results), and uncon-
trolled results were automatically eliminated by the BIOMIC system prior to
analysis. In the present study, fluconazole and voriconazole S, SDD, and R
results for each yeast species were stratified by year of collection, geographic
region, clinical specimen type, and hospital location.
RESULTS
Isolation rates by species. A total of 205,329 yeast isolates
were collected and tested at 134 study sites between June 1997
and December 2005 (Table 1). Candida species accounted for
95.2 to 96.3% of all isolates in each study year (overall, 95.7%).
A total of 22 different species of Candida were isolated, of
which C. albicans was the most common (overall, 65.6% of all
Candida spp.). A decreased rate of isolation of C. albicans was
noted when the first 3 years of the study (1997 to 2000, 70.9%
of all Candida spp.) were compared with the subsequent 5-year
time period (2001 to 2005, 63.5%), although the rates of iso-
lation over the latter time period did not show a continued
declining trend. In contrast, slightly increased rates of isolation
of C. glabrata (10.2% to 11.4%), C. tropicalis (5.4% to 7.5%),
and C. parapsilosis (4.8% to 6.6%) were noted when the time
periods 1997 to 2000 and 2001 to 2005 were compared. Similar
to that seen with C. albicans, the annual isolation rates for each
of these species were relatively stable for the years 2001 to
2005. The rates of isolation of C. krusei, C. guilliermondii, C.
lusitaniae, C. kefyr, C. rugosa, and C. famata did not vary sig-
nificantly over the 8.5-year study period. The rates of isolation
of the remaining 12 species remained quite low; however, the
increased detection of these species, especially in the last 3
years of the study, is evidence of increased efforts to identify
clinical isolates of Candida to the species level in recent years.
Among the noncandidal yeasts, Cryptococcus neoformans
(33% of 8,821 isolates), Saccharomyces spp. (11.3%), Tricho-
sporon spp. (10.7%), and Rhodotorula spp. (4.2%) were the
most commonly identified species (Table 1). Unfortunately,
33% of the noncandidal yeast isolates were reported as “other”
unidentified yeast species. This indicates a relative shortcom-
ing in the commercial yeast identification systems and/or
financial or policy constraints in the clinical laboratories that
may need attention in the future.
Fluconazole and voriconazole susceptibilities of Candida
spp. Table 2 summarizes the in vitro susceptibilities of 141,282
and 137,487 isolates of Candida spp. to fluconazole and vori-
conazole, respectively, as determined by CLSI disk diffusion
testing (16). These isolates were obtained from 124 institutions
in 35 countries during the period from 2001 through 2005. The
percentages of isolates in each category (S, SDD, and R) were
90.1%, 3.6%, and 6.2% and 94.8%, 2.1%, and 3.1% for flu-
conazole and voriconazole, respectively. Fluconazole was most
active (90% S) against C. albicans (97.9% S), C. tropicalis
(90.4% S), C. parapsilosis (93.3% S), C. lusitaniae (92.6% S), C.
kefyr (95.6% S), C. dubliniensis (97.6% S), C. pelliculosa (90.3%
S), C. pulcherrima (93.8% S), and C. intermedia (100% S).
Decreased susceptibility to fluconazole (75% S) was seen
with C. glabrata (68.9% S), C. krusei (9.2% S), C. guilliermondii
(73.9% S), C. rugosa (43.8% S), C. inconspicua (23.4% S), C.
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norvegensis (48.5% S), C. lipolytica (64.9% S), C. zeylanoides
(66.7% S), C. valida (20.0% S), and C. humicola (50.0% S).
Thus, despite the fact that 90% of all clinical isolates of
Candida were susceptible to fluconazole, these data demon-
strate that 10 of the 22 species identified in this survey exhibit
decreased susceptibility on the order of that seen with the
well-known resistant species C. glabrata and C. krusei.
As noted previously (26), voriconazole was more active than
fluconazole against most species of Candida with the exception
of C. tropicalis (90.4% S to fluconazole versus 88.5% S to
voriconazole), C. intermedia (100% S to both), C. haemulonii
(87.5% S to both), and C. humicola (50% S to both). Although
voriconazole was more active than fluconazole against C.
rugosa (64.1% S versus 43.8% S, respectively), C. lipolytica
(75.0% S versus 64.9% S, respectively), and C. valida (75.0% S
versus 20.0% S, respectively), these species were considerably
less susceptible and more resistant (14.6% to 25.1%) to vori-
conazole than all other species of Candida.
A total of 8,545 isolates encompassing 21 different species of
Candida were found to be resistant to fluconazole (Table 3).
Whereas voriconazole was active (75% S) against flucon-
azole-resistant isolates of C. krusei (79.1% S), C. inconspicua
(83.9% S), C. norvegensis (85.7% S), C. dubliniensis (75.0% S),
C. sake (100% S), and C. pulcherrima (100% S), activity was
quite poor against the remaining 15 species. Notably, less than
30% of fluconazole-resistant isolates of C. albicans (28.8% S),
TABLE 1. Species distribution of Candida and other yeast isolates by yeara
Organism
1997–2000 2001 2002 2003 2004 2005
No. of
isolates
tested
% of total
isolates
tested
No. of
isolates
tested
% of total
isolates
tested
No. of
isolates
tested
% of total
isolates
tested
No. of
isolates
tested
% of total
isolates
tested
No. of
isolates
tested
% of total
isolates
tested
No. of
isolates
tested
% of total
isolates
tested
Candida spp. 55,229 95.8 21,804 96.3 24,680 95.3 33,002 95.2 33,406 95.6 28,387 95.9
C. albicans 39,152 67.9 14,268 63.0 15,147 58.5 20,624 59.5 20,988 60.0 18,723 63.2
C. glabrata 5,634 9.8 2,431 10.7 2,635 10.2 3,993 11.5 3,904 11.2 3,189 10.8
C. tropicalis 2,996 5.2 1,634 7.2 1,838 7.1 2,504 7.2 2,520 7.2 2,151 7.3
C. parapsilosis 2,633 4.6 1,501 6.6 1,632 6.3 2,416 7.0 2,234 6.4 1,588 5.4
C. krusei 1,207 2.1 544 2.4 639 2.5 884 2.6 773 2.2 678 2.3
C. guilliermondii 367 0.6 163 0.7 239 0.9 263 0.8 237 0.7 186 0.6
C. lusitaniae 276 0.5 122 0.5 131 0.5 212 0.6 209 0.6 161 0.5
C. kefyr 182 0.3 86 0.4 87 0.3 171 0.5 183 0.5 171 0.6
C. rugosa 35 0.1 151 0.7 150 0.6 117 0.3 51 0.2 33 0.1
C. famata 123 0.2 54 0.2 110 0.4 90 0.3 121 0.4 87 0.3
C. inconspicua 9 0.02 30 0.1 44 0.2 113 0.3 89 0.3 78 0.3
C. norvegensis 11 0.02 32 0.1 18 0.1 42 0.1 43 0.1 36 0.1
C. dubliniensis 1 0.01 19 0.1 26 0.1 18 0.1 50 0.1 56 0.2
C. lipolytica 7 0.01 14 0.1 14 0.1 25 0.1 27 0.1 17 0.1
C. zeylanoides 4 0.01 19 0.1 5 0.02 13 0.04 13 0.04 7 0.02
C. pelliculosa 1 0.01 14 0.1 12 0.1 12 0.03 9 0.03 15 0.1
C. sake 1 9 0.03 2 0.01 8 0.02 13 0.04
C. pulcherrima 4 0.01 5 0.01 7 0.02
C. valida 7 0.02 2 0.01 6 0.02
C. intermedia 7 0.03 2 0.01
C. haemulonii 2 0.01 2 0.01 2 0.01 2 0.01
C. humicola 1 0.01 1 0.01
Candida spp.
NOS
2,591 4.5 721 3.2 1,935 7.5 1,593 4.6 1,937 5.5 1,181 4.0
Other yeasts 2,442 4.2 849 3.7 1,210 4.7 1,547 4.5 1,548 4.4 1,225 4.1
Cryptococcus
neoformans
688 1.2 312 1.4 575 2.2 463 1.3 464 1.3 420 1.4
Trichosporon
spp.
252 0.4 134 0.6 118 0.5 139 0.4 147 0.4 151 0.5
Saccharomyces
spp.
247 0.4 101 0.4 141 0.5 200 0.6 143 0.4 165 0.6
Rhodotorula
spp.
81 0.1 17 0.1 42 0.2 80 0.2 91 0.3 56 0.2
Blastoschizomyes
capitatus
1 0.01 17 0.1 22 0.1 16 0.04 14 0.04 16 0.1
Cryptococcus
spp.
3 0.01 17 0.1 12 0.1 43 0.1 28 0.1 29 0.1
Pichia spp. 7 0.01 5 0.02 7 0.03 15 0.04 53 0.2 13 0.04
Hansenula spp. 10 0.02 2 0.01 9 0.03 2 0.01 1 0.01 1 0.01
Debaryomyces
spp.
1 0.01 1 0.01
Other yeasts
NOS
1,157 2.0 244 1.1 284 1.1 589 1.7 606 1.7 373 1.3
Total 57,675 22,653 25,890 34,657 34,954 29,612
a Includes all specimen types and all locations in hospitals from 134 institutions in 40 countries.
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C. glabrata (17.3% S), C. tropicalis (17.7% S), and C. rugosa
(26.5% S) remained susceptible to voriconazole. Cross-resis-
tance between fluconazole and voriconazole is clearly more
pronounced for some species of Candida than for others, al-
though all are affected to some degree, emphasizing the im-
portance of both species identification and antifungal suscep-
tibility testing in the settings of candidal infection with prior
azole exposure (11, 18, 20, 40, 41).
Trends in resistance to fluconazole among Candida spp.
over an 8.5-year period. There was no consistent trend towards
increasing resistance to fluconazole detected among the com-
mon species C. albicans, C. glabrata, or C. tropicalis over the
8.5-year time period (Table 4). Likewise, consistently high lev-
els of resistance were seen among C. glabrata, C. krusei, C.
guilliermondii, C. inconspicua, and C. norvegensis. Resistance
remained high among C. rugosa, C. famata, C. lipolytica, and C.
zeylanoides for the years 2001 through 2004 but was 6% for
all four species in 2005. The reasons for such a decrease in
resistance are unclear, and the results are likely spurious due to
relatively few isolates of these species being tested in 2005.
A slight increase in resistance was noted among C. parapsi-
losis and C. lusitaniae when the time periods 1997 to 2000 and
2001 to 2005 were compared (2.5% versus 3.7% for C. parap-
silosis and 2.9% versus 4.7% for C. lusitaniae). Although the
number of isolates was small, both C. pulcherrima (25 to 50%
R) and C. valida (50 to 71.4% R) appear to be newly recog-
nized fluconazole-resistant species over the last 3 years (2003
to 2005).
Trends in resistance to voriconazole among Candida spp.,
2001 to 2005. Voriconazole has been tested in the ARTEMIS
Global Surveillance Program since its introduction into clinical
use in 2001 (Table 5). Overall, the rates of resistance by year
were 2.6%, 3.1%, 3.5%, 3.3%, and 3.0% for the years 2001 to
2005, respectively. Although increases in resistance to vori-
conazole were observed for several species between 2001
and 2003 (26), this was not sustained for any species over the
next 2 years (Table 5). Thus, resistance to voriconazole
among Candida spp. is not negligible but no significant trend
towards increasing resistance can be identified over the first
5 years of clinical use.
Geographic variation in the susceptibilities of C. albicans, C.
glabrata, and C. tropicalis to fluconazole and voriconazole. Ta-
ble 6 presents the in vitro susceptibility results for fluconazole
and voriconazole tested against the three most common spe-
cies of Candida, C. albicans, C. glabrata, and C. tropicalis,
stratified by geographic region for the time period from 2001 to
2005. Low rates of resistance to both fluconazole and voricon-
azole were detected among isolates of C. albicans from all
regions, although isolates from North America were more re-
sistant than those from other regions.
As noted previously (26), the resistance rates for both flu-
conazole and voriconazole among isolates of C. glabrata varied
considerably among the various geographic regions. The low-
est rates of resistance to both agents were seen in the Asia-
Pacific region and the highest in North America. Although
voriconazole was more active than fluconazole against isolates
TABLE 2. In vitro susceptibilities of Candida spp. to fluconazole
and voriconazole as determined by CLSI disk diffusion testinga
Species
Fluconazoleb Voriconazoleb
No. of
isolates
tested
% S % R
No. of
isolates
tested
% S % R
C. albicans 89,750 97.9 1.5 87,191 98.4 1.2
C. glabrata 16,152 68.9 15.8 15,824 82.2 10.1
C. tropicalis 10,647 90.4 4.4 10,306 88.5 5.8
C. parapsilosis 9,371 93.3 3.6 9,041 96.8 1.9
C. krusei 3,518 9.2 77.8 3,448 82.9 7.7
C. guilliermondii 1,088 73.9 10.7 1,056 91.3 5.2
C. lusitaniae 835 92.6 4.7 818 96.6 2.1
C. kefyr 698 95.6 3.4 686 98.3 1.3
C. rugosa 502 43.8 47.8 479 64.1 25.1
C. famata 462 80.1 10.6 446 89.5 5.4
C. inconspicua 354 23.4 53.4 351 90.9 4.8
C. norvegensis 171 48.5 36.8 170 94.1 1.8
C. dubliniensis 169 97.6 2.4 168 99.4 0.6
C. lipolytica 97 64.9 30.9 96 75.0 14.6
C. pelliculosa 62 90.3 4.8 61 96.7 3.3
C. zeylanoides 57 66.7 24.6 55 81.8 7.3
C. sake 33 84.8 9.1 33 97.0 3.0
C. pulcherrima 16 93.8 6.3 17 100.0 0.0
C. valida 15 20.0 66.7 16 75.0 18.8
C. intermedia 9 100.0 0.0 9 100.0 0.0
C. haemulonii 8 87.5 12.5 8 87.5 12.5
C. humicola 2 50.0 50.0 2 50.0 50.0
Candida spp.c 7,367 86.8 8.2 7,205 92.9 4.7
a Isolates were obtained from 124 institutions.
b Fluconazole and voriconazole disk diffusion testing was performed in accor-
dance with CLSI document M44-A (16). The interpretive breakpoints (zone
diameters) were as follows: S, 19 mm (fluconazole) and 17 mm (voricon-
azole); R, 14 mm (fluconazole) and 13 mm (voriconazole).
c Candida species not otherwise identified.
TABLE 3. In vitro susceptibilities of fluconazole-resistant isolates
of Candida spp. to voriconazole as determined by CLSI disk
diffusion testinga
Species No. of isolatestested % S % SDD % R
C. albicans 1,289 28.8 8.3 62.9
C. glabrata 2,456 17.3 23.2 59.5
C. tropicalis 457 17.7 13.6 68.7
C. parapsilosis 319 36.7 20.7 42.6
C. krusei 2,674 79.1 11.4 9.4
C. guilliermondii 113 47.8 17.7 34.5
C. lusitaniae 36 52.8 16.7 30.6
C. kefyr 23 65.2 4.3 30.4
C. rugosa 230 26.5 21.7 51.7
C. famata 47 31.9 27.7 40.4
C. inconspicua 186 83.9 8.1 8.1
C. norvegensis 63 85.7 9.5 4.8
C. dubliniensis 4 75.0 25.0
C. lipolytica 30 30.0 30.0 40.0
C. pelliculosa 3 33.3 66.7
C. zeylanoides 13 38.5 30.8 30.8
C. sake 3 100.0
C. pulcherrima 1 100.0
C. valida 11 63.6 9.1 27.3
C. haemulonii 1 100.0
C. humicola 1 100.0
Candida spp.b 585 36.4 16.1 47.5
a Isolates were obtained from 124 institutions. The zone diameters for the
voriconazole disk diffusion susceptibility categories were as follows: S, 17 mm;
SDD, 14 to 16 mm; R, 13 mm.
b Candida species not otherwise identified.
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of C. glabrata from all five regions, as resistance to fluconazole
increased so did resistance to voriconazole.
The lowest rates of resistance to both azoles among C. tropi-
calis isolates were seen in the Africa/Middle East region. Al-
though the rates of resistance in North America were higher
than those in the Africa/Middle East region, the highest rates
of resistance to both azoles were seen in the Asia-Pacific re-
gion. In contrast to that seen with virtually all other species of
Candida, C. tropicalis isolates were generally more resistant to
voriconazole than to fluconazole. This was true in all geo-
graphic regions with the exception of the Asia-Pacific and
Africa/Middle East regions. At present, we have no mechanis-
tic explanation for this phenomenon, although the differences
in resistance rates were generally only 1 to 1.5% in favor of
fluconazole.
Variation in the frequency of isolation and the antifungal
susceptibility profile of C. albicans, C. glabrata, and C. tropicalis
by clinical service. The clinical services reporting the isolation
of C. albicans, C. glabrata, and C. tropicalis from patient spec-
imens included the hematology-oncology service, medical and
surgical services, intensive care units (ICUs) (medical, surgical,
and neonatal), and dermatology, urology, and outpatient ser-
vices (Table 7). Those isolates from services with only a few
isolates and those for which a clinical service was not specified
were included in the category “other NOS” (not otherwise
specified).
C. albicans was isolated most frequently from hospitalized
patients from the medical and ICU services and from outpa-
tients and was the least common from the dermatology and
urology services. Resistance to both fluconazole and voricon-
azole was low across all services, with the lowest resistance
rates seen among isolates from the outpatient service.
C. glabrata was isolated most frequently from the medical
and ICU services, although the highest proportion of Candida
isolates that were C. glabrata was seen with the urology service
(16% of all Candida isolates). The lowest total number of C.
glabrata isolates and the lowest proportion of Candida isolates
that were C. glabrata (4%) were seen with the dermatology
service. The rates of resistance to both fluconazole and vori-
conazole were highest among C. glabrata isolates obtained
from the hematology-oncology service and lowest among iso-
lates obtained from the urology service.
The largest number of C. tropicalis isolates originated from
patients hospitalized in the medical and ICU services. This
species accounted for a greater proportion of the Candida
isolates obtained from the ICU (10.5%) than from other ser-
vices (8%; range, 3.4 to 9.8%). C. tropicalis accounted for only
3.4% of all Candida isolates from the dermatology service and
4.8% of all isolates from the outpatient service. The lowest
rates of resistance to fluconazole and voriconazole were seen
among C. tropicalis isolates obtained from the outpatient ser-
vice, followed by those obtained from the hematology-oncol-
ogy and surgical services. The most resistant isolates came
from the urology service.
Variation in the frequency of isolation and the antifungal
susceptibility profile of C. albicans, C. glabrata, and C. tropicalis
by clinical specimen type. The major specimen types yielding
C. albicans, C. glabrata, and C. tropicalis as putative pathogens
included blood, normally sterile body fluid (NSBF), urine,
respiratory tract, skin and soft tissue, and genital specimens
TABLE 4. Trends in in vitro resistance to fluconazole among Candida spp. as determined by CLSI disk diffusion
testing over an 8.5-year perioda
Species
1997–2000 2001 2002 2003 2004 2005
No. of isolates
tested % R
No. of isolates
tested % R
No. of isolates
tested % R
No. of isolates
tested % R
No. of isolates
tested % R
No. of isolates
tested % R
C. albicans 39,152 0.9 14,268 1.0 15,147 1.5 20,576 1.4 20,988 1.6 18,723 1.6
C. glabrata 5,634 19.2 2,431 18.3 2,635 14.7 3,993 16.9 3,904 14.3 3,189 15.2
C. tropicalis 2,996 3.6 1,634 3.0 1,838 6.6 2,504 5.0 2,520 3.5 2,151 3.8
C. parapsilosis 2,633 2.5 1,501 4.2 1,632 3.9 2,416 3.1 2,234 3.3 1,588 4.2
C. krusei 1,207 65.8 544 70.4 639 78.9 884 80.2 773 78.1 678 79.2
C. guilliermondii 367 12.5 163 11.7 239 10.5 263 8.0 237 10.1 186 14.5
C. lusitaniae 276 2.9 122 6.6 131 4.6 212 2.4 209 4.8 161 6.2
C. kefyr 182 3.3 86 2.3 87 5.7 171 2.9 183 3.8 171 2.9
C. rugosa 35 34.3 151 30.5 150 66.0 117 61.5 51 41.2 33 6.1
C. famata 123 17.1 54 14.8 110 10.9 90 11.1 121 14.0 87 2.3
C. inconspicua 9 55.6 30 60.0 44 47.7 113 46.9 89 58.4 78 57.7
C. norvegensis 11 54.5 32 43.8 18 55.6 42 26.2 43 32.6 36 38.9
C. dubliniensis 1 0.0 19 0.0 26 0.0 18 11.1 50 2.0 56 1.8
C. lipolytica 7 0.0 14 28.6 14 35.7 25 48.0 27 33.3 17 0.0
C. pelliculosa 1 0.0 14 0.0 12 0.0 12 0.0 9 0.0 15 20.0
C. zeylanoides 4 0.0 19 52.6 5 20.0 13 23.1 13 0.0 7 0.0
C. sake 1 0.0 9 11.1 2 0.0 8 12.5 13 7.7
C. pulcherrima 3 33.3 8 25.0 4 50.0 4 50.0
C. valida 7 71.4 2 50.0 6 66.7
C. intermedia 7 0.0 2 0.0
C. haemulonii 2 0.0 2 0.0 2 0.0 2 50.0
C. humicola 1 100.0 1 0.0
Candida spp.b 2,591 10.5 721 9.6 1,935 5.2 1,593 11.2 1,937 8.3 1,181 7.9
a Includes all specimen types and all hospital locations in 134 institutions. Zone diameter, 14 mm. Fluconazole disk diffusion testing was performed in accordance
with CLSI document M44-A (16).
b Candida species not otherwise defined.
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(Table 8). Those isolates from uncommon specimen types and
those for which a specimen type was not recorded were
grouped under “miscellaneous NOS.”
C. albicans constituted more than 70% of the Candida spp.
isolated from respiratory (71%) and genital (79%) tract spec-
imens but accounted for only 43% of Candida sp. isolates
obtained from blood cultures. There was very little variation in
the rates of resistance of C. albicans to either fluconazole or
voriconazole among the different specimen types. Isolates from
genital specimens had the lowest frequency of resistance to
both agents.
C. glabrata accounted for 14% of all Candida spp. isolated
from blood and NSBF and for 19% of those isolated from
urine but for less than 10% of isolates from other sites of
infection. The resistance rates to fluconazole and voriconazole
were highest for isolates from skin and soft tissue specimens
and did not vary appreciably across the other specimen types.
C. tropicalis accounted for 12% of all bloodstream isolates of
TABLE 5. Trends in in vitro resistance to voriconazole among Candida spp. as determined by CLSI disk diffusion
testing over a 5-year perioda
Species
2001 2002 2003 2004 2005
No. of isolates
tested % R
No. of isolates
tested % R
No. of isolates
tested % R
No. of isolates
tested % R
No. of isolates
tested % R
C. albicans 11,980 0.8 15,086 1.1 20,570 1.1 20,939 1.5 18,616 1.5
C. glabrata 2,123 9.8 2,625 8.5 3,991 11.5 3,904 10.4 3,181 9.6
C. tropicalis 1,350 4.7 1,820 8.1 2,490 6.7 2,511 4.9 2,135 4.5
C. parapsilosis 1,205 1.9 1,627 2.3 2,411 1.5 2,221 1.9 1,577 1.9
C. krusei 474 8.0 635 6.1 887 8.1 769 8.3 683 7.9
C. guilliermondii 142 4.2 235 5.5 259 4.6 236 5.1 184 6.5
C. lusitaniae 106 2.8 129 1.6 211 1.9 209 1.4 163 3.1
C. kefyr 75 1.3 85 1.2 171 0.0 183 1.1 172 2.9
C. rugosa 129 3.1 149 37.6 117 37.6 51 29.4 33 3.0
C. famata 39 10.3 110 1.8 90 7.8 120 8.3 87 1.1
C. inconspicua 30 6.7 43 4.7 113 5.3 88 5.7 77 2.6
C. norvegensis 31 0.0 18 0.0 42 2.4 43 4.7 36 0.0
C. dubliniensis 19 0.0 26 0.0 18 0.0 48 2.1 51 0.0
C. lipolytica 13 7.7 14 42.9 25 12.0 27 14.8 17 0.0
C. pelliculosa 14 0.0 12 0.0 12 0.0 9 0.0 14 14.3
C. zeylanoides 17 11.8 5 20.0 13 7.7 13 0.0 7 0.0
C. sake 1 0.0 9 0.0 2 0.0 8 0.0 13 7.7
C. pulcherrima 4 0.0 5 0.0 8 0.0
C. valida 7 0.0 2 50.0 7 28.6
C. intermedia 7 0.0 2 0.0
C. haemulonii 2 0.0 2 0.0 2 0.0 2 50.0
C. humicola 1 100.0 1 0.0
Candida spp.b 572 4.0 1,935 2.9 1,591 7.3 1,924 4.5 1,183 4.9
a Isolates were obtained from 124 institutions. Zone diameter,13 mm. Voriconazole disk diffusion testing was performed in accordance with CLSI document M44-A
(16).
b Candida species not otherwise defined.
TABLE 6. Geographic variation in the in vitro susceptibilities of C. albicans, C. glabrata, and C. tropicalis to fluconazole and voriconazolea
Region Antifungalagent
C. albicans C. glabrata C. tropicalis
No. of isolates
tested % R
No. of isolates
tested % R
No. of isolates
tested % R
Asia-Pacific Fluconazole 18,125 0.9 3,368 13.5 3,120 8.1
Voriconazole 17,298 0.9 3,259 7.7 2,989 4.7
Europe Fluconazole 52,127 1.2 8,642 16.0 3,930 2.6
Voriconazole 50,926 1.1 8,492 9.9 3,817 3.5
Africa/Middle East Fluconazole 4,566 0.6 564 19.1 350 2.9
Voriconazole 4,529 0.3 541 9.1 348 2.6
Latin America Fluconazole 10,288 2.4 1,472 14.0 2,525 3.0
Voriconazole 9,830 1.9 1,434 9.6 2,423 4.4
North America Fluconazole 4,644 5.1 2,106 20.5 740 3.6
Voriconazole 4,608 3.7 2,098 15.3 729 4.7
a Isolates were obtained from 124 institutions. Fluconazole and voriconazole disk diffusion testing was performed in accordance with CLSI document M44-A (16).
The interpretive breakpoints (zone diameters) for resistance were as follows: fluconazole, 14 mm; voriconazole, 13 mm.
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Candida and for 14% of all urinary tract isolates but was less
common (10%) as an agent of candidiasis among other spec-
imen types. The rates of resistance were highest for urinary
tract isolates and lowest for respiratory tract isolates.
Activities of fluconazole and voriconazole against other op-
portunistic yeasts and yeast-like fungi. Although uncommon,
the number and types of noncandidal yeasts isolated from
clinical specimens have continued to increase over the dura-
tion of this study (Tables 1 and 9). Cryptococcus neoformans
continues to predominate, but the numbers of isolates of Sac-
charomyces, Trichosporon, and Rhodotorula species are also
substantial. In general, these yeast-like fungi are considerably
less susceptible to fluconazole than are Candida spp.
Among the species of Cryptococcus, it is important to note
TABLE 7. Susceptibilities of C. albicans, C. glabrata, and C. tropicalis to fluconazole and voriconazole by clinical servicea
Clinical service
(total no. of isolates)
Antifungal
agent
C. albicans C. glabrata C. tropicalis
No. of isolates
tested % R
No. of isolates
tested % R
No. of isolates
tested % R
Hematology-oncology (8,432) Fluconazole 5,154 2.2 1,089 22.0 718 3.5
Voriconazole 5,062 2.0 1,069 15.7 693 4.5
Medical (33,681) Fluconazole 20,958 1.4 3,637 15.2 3,193 4.2
Voriconazole 20,409 1.3 3,574 9.8 3,098 6.0
Surgical (8,869) Fluconazole 5,359 1.5 1,189 12.4 868 3.5
Voriconazole 5,235 1.4 1,170 7.9 831 4.5
ICU (18,691) Fluconazole 11,340 1.4 2,389 15.2 1,962 3.7
Voriconazole 11,054 1.2 2,330 10.4 1,919 7.0
Dermatology (2,519) Fluconazole 1,334 2.4 109 16.5 86 3.5
Voriconazole 1,313 1.6 106 8.5 79 5.1
Urology (1,293) Fluconazole 775 1.9 212 13.2 124 6.5
Voriconazole 759 2.0 210 4.8 122 7.4
Outpatient (11,621) Fluconazole 7,690 1.2 901 19.2 559 2.5
Voriconazole 7,592 0.8 894 12.2 550 2.4
Other NOS (38,649) Fluconazole 22,710 2.0 5,048 15.8 2,807 5.8
Voriconazole 21,812 1.4 4,947 10.2 2,696 7.2
a Isolates were obtained from 124 institutions. Disk diffusion testing was performed in accordance with CLSI document M44-A (16). The interpretive breakpoints
(zone diameters) for resistance were as follows: fluconazole, 14 mm; voriconazole, 13 mm.
TABLE 8. Susceptibilities of C. albicans, C. glabrata, and C. tropicalis to fluconazole and voriconazole by specimen typea
Specimen type/site
(total no. of isolates)
Antifungal
agent
C. albicans C. glabrata C. tropicalis
No. of isolates
tested % R
No. of isolates
tested % R
No. of isolates
tested % R
Blood (14,887) Fluconazole 6,443 1.4 2,078 16.7 1,816 4.0
Voriconazole 6,337 1.2 2,030 11.8 1,771 5.5
NSBF (6,055) Fluconazole 3,608 1.4 809 14.3 552 4.5
Voriconazole 3,535 1.4 795 8.3 542 5.2
Urine (18,168) Fluconazole 9,296 1.4 3,381 16.2 2,585 5.5
Voriconazole 9,059 1.2 3,330 11.2 2,479 7.9
Respiratory (39,523) Fluconazole 28,114 1.9 3,719 15.7 2,972 3.1
Voriconazole 27,421 1.5 3,650 9.9 2,897 4.2
Skin/soft tissue (8,290) Fluconazole 4,107 1.6 627 19.0 608 4.9
Voriconazole 4,007 1.2 621 12.7 586 5.3
Genital (31,157) Fluconazole 24,574 0.8 2,785 16.6 507 4.9
Voriconazole 23,658 0.7 2,691 8.7 484 6.6
Miscellaneous NOS (23,303) Fluconazole 13,608 2.0 2,753 13.5 1,607 4.9
Voriconazole 13,174 1.6 2,707 8.9 1,547 5.1
a Isolates were obtained from 124 institutions. Disk diffusion testing was performed in accordance with CLSI document M44-A (16). The interpretive breakpoints
(zone diameters) for resistance were as follows: fluconazole, 14 mm; voriconazole, 13 mm.
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the rather poor activity of fluconazole against isolates of C.
gattii (Table 9). This species has long been noted to be an
important opportunistic pathogen in tropical and subtropical
climates and has recently gained importance due to an out-
break of C. gattii on Vancouver Island, BC, Canada (10, 15,
39). The decreased susceptibility of this species of Cryptococcus
to fluconazole is similar to that observed by other investigators
(14, 42, 43), although a recent report from Africa found low
MICs to fluconazole and other azoles (15). Both C. gattii and
C. neoformans were very susceptible to voriconazole in the
present study (Table 9).
Both Saccharomyces cerevisiae and various species of Tricho-
sporon appear to be moderately susceptible to fluconazole. It is
interesting that T. mucoides, T. inkin, and T. ovoides appear to
be considerably more susceptible to fluconazole than T. asahii
and T. beigelii/T. cutaneum. Voriconazole exhibited very good
activity against both Saccharomyces and Trichosporon species
with the exception of T. beigelii/T. cutaneum.
Rhodotorula spp., including R. rubra/mucilaginosa and R.
glutinis, are often resistant to both fluconazole and voriconazole.
Amphotericin B continues to be the antifungal agent of choice for
the treatment of infections due to this opportunistic yeast (5).
Fluconazole has only modest activity against isolates of Blas-
toschizomyces capitatus and Pichia (Hansenula) spp. Voricon-
azole appears to be active against these yeasts, although clin-
ical experience in treating infections due to these rare yeasts is
lacking (24, 44).
Similar to that seen with the Candida species, isolates of
non-Candida yeasts that are resistant to fluconazole also show
increased resistance to voriconazole (Table 10). These organ-
isms could be quite problematic when encountered in an im-
munocompromised host given the fact that, in addition to the
acquired azole resistance, they also exhibit intrinsic resistance
to the echinocandin class of antifungal agents (24, 40).
DISCUSSION
In this most recent summary of the data from the ARTEMIS
DISK Global Surveillance Program, we report fluconazole and
voriconazole susceptibility results for more than 200,000 clin-
ical isolates of Candida and other opportunistic yeast patho-
gens from throughout the world. The value of such a large
database is that for the more common species of Candida, we
can assess trends in resistance over time (Tables 4 and 5), by
geographic region (Table 6), by clinical service (Table 7), and
by specimen type (Table 8). Of greater potential value is the
data pertaining to the less common species of Candida and
other yeasts (Tables 1 to 3, 9, and 10). These relatively rare
pathogens are unlikely to be familiar to both clinicians and
microbiologists, and there is little or no data regarding prog-
nosis or optimal treatment strategies (17, 24, 31, 32, 40, 44).
Given the ubiquitous use of azoles in prophylaxis, empirical,
and directed therapies (4, 20, 40, 41), it is important to know
the activities of the systemically active agents, such as flucon-
azole and voriconazole, against these organisms (40, 41, 44).
The fact that the less common species of Candida exhibit
decreased susceptibility to fluconazole, and in some instances
to voriconazole (Table 2), is important, as these organisms
TABLE 10. In vitro susceptibilities of fluconazole-resistant isolates
of non-Candida yeasts to voriconazole as determined by
CLSI disk diffusion testinga
Species No. of isolatestested % S % SDD % R
C. neoformans 228 79.8 6.6 13.6
C. gattii 3 66.7 0.0 33.3
Cryptococcus spp.b 18 27.8 22.2 50.0
Saccharomyces spp.c 1 0.0 0.0 100.0
S. cerevisiae 43 34.9 25.6 39.5
Trichosporon spp.d 38 55.3 21.1 23.7
T. beigelii/T. cutaneum 15 13.3 6.7 80.0
T. asahii 8 50.0 0.0 50.0
T. inkin 1 100.0 0.0 0.0
Rhodotorula spp.e 104 19.2 8.7 72.1
R. rubra/mucilaginosa 41 14.6 7.3 78.0
R. glutinis 13 23.1 0.0 76.9
Blastoschizomyces capitatus 10 60.0 10.0 30.0
Pichia spp.f 8 87.5 12.5 0.0
Hansenula spp.g 1 100.0 0.0 0.0
a Isolates were obtained from 124 institutions. The zone diameters for the
voriconazole disk diffusion susceptibility categories were as follows: S, 17 mm;
SDD, 14 to 16 mm; R, 13 mm.
b Cryptococcus species other than C. neoformans and C. gattii.
c Saccharomyces species not otherwise identified.
d Trichosporon species not otherwise identified.
e Rhodotorula species not otherwise identified.
f Pichia species not otherwise identified.
g Hansenula species not otherwise identified.
TABLE 9. In vitro susceptibilities of non-Candida yeasts to
fluconazole and voriconazole as determined by
CLSI disk diffusion testinga
Species
Fluconazoleb Voriconazoleb
No. of
isolates
tested
% S % R
No. of
isolates
tested
% S % R
C. neoformans 2,230 78.0 10.4 2,209 97.1 1.7
C. gattii 28 57.1 10.7 28 96.4 3.6
Cryptococcus spp.c 108 71.3 16.7 108 86.1 9.3
Saccharomyces spp.d 41 90.2 2.4 37 97.3 2.7
S. cerevisiae 709 88.6 6.3 697 95.1 3.0
Trichosporon spp.e 443 84.7 9.0 422 95.0 2.4
T. beigelii/T. cutaneum 125 77.6 12.0 123 83.7 12.2
T. mucoides 51 94.1 0.0 51 100.0 0.0
T. asahii 53 79.2 15.1 53 92.5 7.5
T. inkin 13 92.3 7.7 13 100.0 0.0
T. ovoides 3 100.0 0.0 3 100.0 0.0
Rhodotorula spp.f 210 45.2 49.0 209 56.9 37.3
R. rubra/mucilaginosa 52 17.3 78.8 52 25.0 67.3
R. glutinis 24 41.7 54.2 24 58.3 41.7
Blastoschizomyces
capitatus
86 81.4 11.6 86 91.9 3.5
Pichia spp.g 94 86.2 9.6 92 97.8 0.0
Hansenula spp.h 15 71.4 7.1 15 93.3 6.7
Debaryomyces spp.i 2 100.0 0.0 2 100.0 0.0
a Isolates were obtained from 124 institutions.
b Fluconazole and voriconazole disk diffusion testing was performed in accor-
dance with CLSI document M44-A (16). The interpretive breakpoints (zone
diameters) were as follows: S, 19 mm (fluconazole) and 17 mm (voricon-
azole); R, 14 mm (fluconazole) and 13 mm (voriconazole).
c Cryptococcus species other than C. neoformans and C. gattii.
d Saccharomyces species not otherwise identified.
e Trichosporon species not otherwise identified.
f Rhodotorula species not otherwise identified.
g Pichia species not otherwise identified.
h Hansenula species not otherwise identified.
i Debaryomyces species not otherwise identified.
1742 PFALLER ET AL. J. CLIN. MICROBIOL.
could emerge as pathogens in immunocompromised patients
who have already been receiving an azole (24, 31, 32). In this
regard, it is also important to understand what to expect with
regard to susceptibility to voriconazole among Candida species
found to break through fluconazole therapy (Table 3) (21).
Species such as C. krusei, C. inconspicua, and C. norvegensis
may emerge during fluconazole therapy due to their intrinsic
resistance to fluconazole yet remain susceptible to voricon-
azole (Table 3). Unfortunately, most other species of Candida
that exhibit acquired resistance to fluconazole also appear
to be significantly less susceptible to voriconazole than their
“fluconazole-naı¨ve” counterparts (Table 3) and are less
likely to respond optimally to treatment with this agent (11,
18, 20, 40, 41).
Among the non-Candida yeasts, there is even less informa-
tion to guide antifungal therapy (24, 26, 44). These organisms
generally appear to be less susceptible to fluconazole than
Candida spp. (Table 9) but, aside from Rhodotorula spp., re-
main susceptible to voriconazole (Table 9). Unfortunately, as
with Candida, fluconazole-resistant isolates of these noncan-
didal yeasts also exhibit decreased susceptibility to voricon-
azole (Table 10). Given their intrinsic resistance to the
echinocandins and their variable response to amphotericin
B, these yeasts may pose considerable problems in the fu-
ture (5, 12, 24, 44).
Overall, the ARTEMIS database can serve as a look into the
future of clinical mycology. At present, the azoles fluconazole
and voriconazole appear to be adequate in their coverage of
the most common species of Candida (Table 2). However, the
weaknesses of both of these agents, as well as posaconazole
and the echinocandins (34), can be seen as we look at the less
common species of Candida and the other opportunistic yeasts
(24). Although any one of these unusual pathogens may never
truly “emerge” to become a major threat in and of itself, in
aggregate these organisms could pose problems among pa-
tients with prior azole exposure. Furthermore, the lack of any
meaningful activity of the echinocandin class against the non-
Candida yeasts and the increasing use of this class of antifungal
agents suggest that these organisms may be prime candidates
to “emerge” as new mycotic threats (12).
The potential value of large antifungal surveillance data-
bases such as that of ARTEMIS is considerable; however, the
value of such information for clinical purposes is weakened
substantially without knowledge of the species identification of
the infecting organism. Thus, it is imperative that clinical lab-
oratories strive to provide rapid and accurate identification of
Candida and other opportunistic yeasts. Although antifungal
susceptibility testing of fluconazole and voriconazole is becom-
ing more accessible (22, 25, 27, 33, 35, 36), in most instances
the species identification alone, coupled with survey data such
as that of ARTEMIS, is sufficient to guide the selection of
initial antifungal therapy. Specific antifungal susceptibility test-
ing may help to optimize therapy in instances where a subop-
timal response is observed to what would ordinarily be consid-
ered adequate therapy (20, 38, 41).
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